European Congress of Radiology - Vienna, Austria – Mar. 07, 2008 – Acceleware Corp. (TSX-V: AXE), a leading developer of acceleration solutions for high-performance computing, today announced the launch of its AxRecon image reconstruction solution for the medical imaging, security, and non-destructive testing markets. Image reconstruction for Computed Tomography (CT) Scanners often takes hours of processing time and represents a major barrier to efficiency for many organizations. Acceleware’s solution reduces the time required to complete this work from hours to minutes to speed up the imaging workflow. AxRecon will be demonstrated at the European Congress of Radiology (ECR) this week in Vienna, Austria, booth #435.
“Our entry into the medical and commercial imaging market space represents a significant growth opportunity for Acceleware, and is consistent with Acceleware’s long-term growth strategy to tackle new markets,” said Sean Krakiwsky, CEO of Acceleware. “The benefits of higher throughput and image quality that are already being realized by early customers of AxRecon™ will help us drive adoption of this product within the broader imaging market.”
The long processing time required for CT image reconstruction limits throughput and quality for companies, clinicians, and researchers. In order to meet the demands of their workload, these users often sacrifice image quality to save on processing time. AxRecon works with existing cone beam CT scanners to eliminate the bottleneck by significantly speeding up filtered back projection computations. This enables medical and commercial users to accelerate the reconstruction of their data and improve the quality of their images without disrupting their current workflow.
The AxRecon solution combines Acceleware’s proprietary software acceleration libraries with the massive parallel processing power of NVIDIA® Graphic Processing Units (GPUs) to dramatically increase the speed of sophisticated computations. AxRecon seamlessly integrates with existing CT scanners with minimal setup. By accelerating algorithms such as filtered back-projection image reconstruction, clients are able to increase the speed of their operations and quality of their end results, while reducing the energy use and physical footprint of their high performance computing systems.
“In biomedical micro-computed tomography applications, the volume dimensions of our reconstructions have increased dramatically over the past few years,” said David Holdsworth of Robarts Imaging. “During the same period, scan times have also been reduced; this makes cone-beam CT reconstruction time the bottleneck that limits workflow in some situations. GPU-based reconstruction is a cost-effective solution for this task, and we have found that Acceleware’s AxRecon product can provide 3D reconstructions up to 50 times faster than a single-CPU.”
Please visit Acceleware at ECR in Booth: #435, taking place this week in Vienna, Austria.
Acceleware develops and markets solutions that enable software vendors to leverage heterogeneous, multi-core hardware environments without having to rewrite their applications for parallel processing. This acceleration abstraction technology results in end-users achieving significant computing speed-ups and migrating vendor applications from single-core processing to multiple-core CPUs, GPUs or other acceleration products.
Acceleware solutions are deployed by companies worldwide to accelerate computer simulation and data processing applications in areas such as electromagnetics, oil & gas, medical and security imaging, industrial and consumer product design, financial, and academic research.
Acceleware's third-generation multi-board GPU solutions can accelerate simulation and processing algorithms by over 35 times, reducing data processing from multiple hours to minutes. Acceleware is a public company on Canada's TSX Venture Exchange under the trading symbol AXE.
Charlee Forbrigger, Marketing Manager, Acceleware Corp., +1.403.249.9099 ext. 287, firstname.lastname@example.org
The TSX Venture Exchange Inc. does not accept responsibility for the adequacy or accuracy of this release.